Cargando…
First report of a very rare complication in a case of nonsmall cell lung carcinoma
While immune checkpoint inhibitors like pembrolizumab are promising agents for nonsmall cell lung carcinoma treatment, increased use is leading to increased immune-related adverse events, including endocrinopathies such as adrenal insufficiency. https://bit.ly/3iMfhUk
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753643/ https://www.ncbi.nlm.nih.gov/pubmed/35035567 http://dx.doi.org/10.1183/20734735.0107-2021 |